The Dawn of Oral Therapies for Diabetic Retinopathy: A Fresh Vision for Treatment?
A recent study presented at Angiogenesis, Exudation, and Degeneration 2026 suggests a potential shift in how diabetic retinopathy (DR) is treated. Early results indicate that danegaptide, an oral medication developed by Breye Therapeutics, may reduce vascular leakage and macular exudation in patients with nonproliferative diabetic retinopathy (NPDR). This development could offer a less invasive alternative to current treatment options.
Understanding the Current Landscape of DR Treatment
Currently, the standard of care for DR often involves intravitreal injections of anti-VEGF (vascular endothelial growth factor) drugs. While effective, these injections require regular visits to a specialist and carry potential risks, including infection and retinal detachment. The possibility of an oral medication like danegaptide offers a more convenient and potentially safer approach, particularly for patients in the early stages of the disease.
Danegaptide: How Does It Work?
The study, conducted across the U.K., Germany, and the U.S., involved 24 adults with NPDR and diabetic macular edema. Researchers found that 55% of patients showed signs of reduced vascular leakage and/or reduced macular exudation after 28 days of oral danegaptide treatment. Importantly, no clinical safety signals were observed during the phase 1b trial. The drug appears to work by targeting a key pathway involved in the development of DR, potentially halting or even reversing the disease process before it progresses to more advanced stages.
Phase 2 Trials on the Horizon
The successful completion of the phase 1b trial has paved the way for a phase 2 randomized clinical trial, which Breye Therapeutics is currently fundraising for. This next phase will be crucial in confirming the efficacy and safety of danegaptide in a larger patient population. The potential to treat DR at earlier stages, before the risk of progression to advanced forms, is a significant step forward.
Beyond Danegaptide: The Growing Pipeline of Oral DR Treatments
Danegaptide isn’t the only oral therapy being investigated for DR. Several pharmaceutical companies are exploring different approaches to address this growing global health concern. This increased investment in oral DR treatments signals a growing recognition of the require for more convenient and patient-friendly options.
Did you know? Diabetic retinopathy is a leading cause of blindness worldwide, affecting millions of people with diabetes.
The Role of Early Detection and Management
While promising, these new therapies underscore the importance of early detection and management of diabetes and DR. Regular eye exams are crucial for identifying DR in its early stages, when treatment is most effective. Lifestyle modifications, such as controlling blood sugar, blood pressure, and cholesterol, also play a vital role in preventing and slowing the progression of the disease.
Future Implications for Telemedicine and Remote Monitoring
The development of oral therapies could also facilitate the integration of telemedicine and remote monitoring into DR care. Patients could potentially be monitored remotely, with medication adjustments made based on their individual responses. This could improve access to care, particularly for patients in rural or underserved areas.
Frequently Asked Questions (FAQ)
- What is diabetic retinopathy? Diabetic retinopathy is damage to the blood vessels in the retina caused by diabetes.
- What are the current treatments for diabetic retinopathy? Current treatments include laser therapy, intravitreal injections, and vitrectomy surgery.
- Is danegaptide currently available? No, danegaptide is still in clinical trials and is not yet available for general use.
- What are the potential benefits of an oral treatment for DR? Oral treatments offer a more convenient and potentially safer alternative to injections.
Pro Tip: If you have diabetes, schedule a comprehensive dilated eye exam at least once a year, or more frequently as recommended by your eye care professional.
Learn more about diabetic retinopathy from the National Eye Institute.
Have questions about your eye health? Share them in the comments below!
Keep reading